Company intelligence / Profile preview
XORTX Therapeutics
Calgary, Alberta, Canadaxortx.com ↗
- Ownership
- Public · XRTX
- Employees
- ~3
- Development stage
- NDA
01
Overview
XORTX’s most advanced program for gout (XORLO™, reformulated oxypurinol) has secured FDA agreement to use the 505(b)(2) pathway and expects an NDA submission by H1 2026. The ADPKD program (XRx‑008) and COVID-related acute kidney injury program are in Phase 2 development. A preclinical candidate targets type 2 diabetic nephropathy. The company’s approach leverages established safety data for oxypurinol to accelerate regulatory timelines.
- Therapeutic areas
- EndocrinologyNephrologyRheumatology
- Modalities
- small molecules (notably xanthine oxidase inhibitors and uric acid lowering agents)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
University of Florida Research Foundation license agreement for use of a uric acid-lowering agent to treat insulin resistanceCollaboration with PKD Foundation on ADPKD research
04
Financials
- Market cap
- $587.6K
- Total revenue
- $0
- Enterprise value
- $-405.2K
Beyond the preview
Go deeper on XORTX Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XORTX Therapeutics.